J&J Releases Interim Phase 1/2 Data for COVID-19 Vaccine

Interim phase 1/2a trial data for Johnson & Johnson’s (J&J) COVID-19 vaccine published in the New England Journal of Medicine showed that the single-dose vaccine elicited an immune response in patients aged 18 to 55 years that lasted for at least 71 days and was generally well-tolerated.

J&J said it anticipates announcing top-line phase 3 data late this month and will file for Emergency Use Authorization shortly after if the vaccine proves safe and effective.

The company is reportedly falling behind its goal of manufacturing 12 million shots of the single-dose vaccine by the end of February but said it believes it will ultimately meet its supply agreements for 2021.